Delisting risk
Soligenix
Develops rare-disease therapeutics and heat-stable biodefense vaccine candidates.
$0.3733
After-hours close−0.00 (−0.93%)
At close$0.3768(−0.84%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 1.76%260.6K sharesInsiders 0.10%15.5K sharesOther 98.14%14.55M shares
Shares outstanding 14.82M · Float 14.72M · 99.3% free float
Institutions13F, as of Mar 31, 2026
15 holders · 260.6K shares · 5 new positions · 8 increased · 3 reduced · 7 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Geode Capital Management, LLC | 120.3K | 0.81% | +39.9K | May 15, 2026 |
| Vanguard Capital Management LLC | 58.4K | 0.39% | +58.4Knew | May 15, 2026 |
| Vanguard Fiduciary Trust Co | 53.9K | 0.36% | +53.9Knew | May 8, 2026 |
| XTX Topco Ltd | 20.8K | 0.14% | −7.1K | May 15, 2026 |
| Morgan Stanley | 3.6K | 0.02% | 0 | May 15, 2026 |
| UBS Group AG | 2.3K | 0.02% | −31.7K | May 5, 2026 |
| Sbi Securities Co., Ltd. | 402 | 0.00% | +400 | Apr 28, 2026 |
| JPMorgan Chase & Co | 305 | 0.00% | +305new | May 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| MJL Manager LLC | 5.20% | 893.6K | 13G | Jun 25, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Christopher J. Schaber | director, officer: CHAIRMAN, CEO AND PRESIDENT | 15.5K | 0.10% | Oct 3, 2025 |
5 ten-percent owners hold 2.4K shares by Form 4, outside the officers-and-directors figure above · 18 people have not refiled in the last 18 months (2.4K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Oct 2, 2025 | Christopher J. Schaberdirector, officer: CHAIRMAN, CEO AND PRESIDENT | Purchase | 15,132 | $1.32 | 15,511 |
CongressHouse and Senate disclosures
Not reported.